Home » Newsletters » BioWorld

BioWorld

Feb. 18, 1992

View Archived Issues

U.S. BIOSCIENCE STILL WAITING FOR FDA MEETING

JOINT VENTURE FOR SWEDISH PEPTIDES

COURT DISMISSES CENTOCOR SUIT

NEORX LICENSES PRE-TARGETING TECHNOLOGY

FDA APPROVES COMBINATION HIV TEST

AMOCO UNIT ACQUIRES ECOVA CORP

HYCOR GETS HISTAMINE TECHNOLOGY

PRIVATE PLACEMENT RAISES $11.6M

CYTOTHERAPEUTICS FILES FOR IPO

TRANSGENIC DEVELOPER MAKING IPO .

LIPO FILES TO OFFER 3M SHARES

$29M OFFERING BY ADVANCED TISSUE

CYTORAD SPIN-OFF RAISES $35M

NEW REPORT ON SEPSIS LIFE SAVER

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...